Knocking Down Hepatic GPR146 Shrinks Plaques in ApoE-Deficient Mice
- Hepatic AAV-mediated GPR146 knockdown was tested in high-fat-fed ApoE-deficient mice, with rosuvastatin as a comparator arm.
- Knockdown reduced plaque burden, circulating cholesterol and plaque inflammation; GPR146 was also up-regulated in macrophage-rich lesion regions.
- In ox-LDL-treated macrophages, silencing GPR146 lowered CD36 and foam-cell formation and dampened pro-inflammatory activation, with JAK-STAT implicated.
💡 Points Based on the abstract
The liver-lipid and macrophage-inflammation claims are mixed in one story, but hepatic knockdown cannot tell you which one cleared the plaque; a macrophage-specific knockout would. GPR146 is an orphan GPCR with no validated agonist or antagonist, so the next hard question is ligandability, and whether any compound could match a statin on top-line efficacy rather than just add to it.
📄 Paper · Biochemical Pharmacology ↗ GPR146 as a therapeutic target: Linking lipid metabolism with macrophage inflammation in atherosclerosis